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ABSTRACT 
 
This study was done in 40 Sudanese patients undergoing major 
pelvic surgery in Khartoum Teaching Hospital (KTH) and Soba 
University Hospital (SUH) in the period from 1 rest May to 31st October 
2001.  
The study aimed at evaluation of the effects of intravenous infusion 
of lignocaine on postoperative bowel function, adequacy of analgesia and 
hospital stay.  
Data was collected using a questionnaire.  
It was found that intravenous infusion of lignocaine postoperatively 
decreases the time of return of bowel sounds, hence reducing 
postoperative paralytic ileus, delaying the onset of postoperative pain and 
reducing hospital stay.  
The recommendation is to encourage the use of intravenous 
lignocaine for abdominal and pelvic operations to reduce the incidence of 
paralytic ileus and postoperative pain.  
 
  
 
 
 
  ﺹ ﺍﻻﻁﺭﻭﺤﺔﻠﺨﻠﻤ
ﺍﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻋﻠﻰ ﺃﺭﺒﻌﻴﻥ ﻤﺭﻴﻀﺎﹰ ﺴﻭﺩﺍﻨﻴﺎﹰ ﻤﻥ ﺍﻟﺠﻨﺴﻴﻥ ﻤﻥ ﺍﻟﺫﻴﻥ ﺃﺠﺭﻴﺕ ﻟﻬﻡ 
ﻋﻤﻠﻴﺎﺕ ﻜﺒﻴﺭﺓ ﺒﺎﻟﺤﻭﺽ ﻓﻲ ﻤﺴﺘﺸﻔﻰ ﺍﻟﺨﺭﻁﻭﻡ ﺍﻟﺘﻌﻠﻴﻤﻲ ﻭﻤﺴﺘﺸﻔﻰ ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻲ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﺎ 
  . ﻡ1002ﻥ ﻤﻥ ﺃﻜﺘﻭﺒﺭ ﻴﺒﻴﻥ ﺃﻭل ﻤﺎﻴﻭ ﺤﺘﻰ ﺍﻟﺤﺎﺩﻯ ﻭﺍﻟﺜﻼﺜ
ﺍﻟﻠﻘﻨﻭﻜﻴﻥ ﺍﻟﻤﻌﻁﻰ ﺒﺎﻟﺯﺭﻕ ﺍﻟﻭﺭﻴﺩﻯ ﻋﻠﻰ ﻭﻅﺎﺌﻑ ﺘﻬﺩﻑ ﺍﻟﺩﺭﺍﺴﺔ  ﺇﻟﻰ ﺘﻘﻴﻴﻡ ﺃﺜﺭ ﻋﻘﺎﺭ 
  . ﺍﻹﻤﻌﺎﺀ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔ ﻭﻜﻔﺎﻴﺘﻪ ﺘﺴﻜﻴﻥ ﺍﻷﻟﻡ ﻭﺒﻘﺎﺀ ﺍﻟﻤﺭﻴﺽ ﺒﺎﻟﻤﺴﺘﺸﻔﻰ
ﺘﻡ ﺘﺠﻤﻴﻊ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﺒﻭﺍﺴﻁﺔ ﺍﻹﺴﺘﺒﻴﺎﻥ، ﻭﻭﺠﺩ ﺃﻥ ﺍﻋﻁﺎﺀ ﺍﻟﻠﻘﻨﻭﻜﻴﻥ ﺒﺎﻟﺯﺭﻕ ﺍﻟﻭﺭﻴﺩﻯ 
ﻠﻴﺔ ﻭﻴﻘﻠل ﻗﺒل ﺍﻟﻌﻤﻠﻴﺔ ﻴﺴﺭﻉ ﻋﻭﺩﺓ ﺼﻭﺕ ﺍﻹﻤﻌﺎﺀ ﻤﻤﺎ ﻴﻘﻠل ﻤﻥ ﺤﺩﻭﺙ ﺍﻟﺸﻠل ﺍﻟﻌﺼﺎﺒﻲ ﺒﻌﺩ ﺍﻟﻌﻤ
  . ﻤﺫﻟﻙ ﺍﻷﻟﻡ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔ ﻭﻤﺩﺓ ﺍﻟﺒﻘﺎﺀ ﺒﺎﻟﻤﺴﺘﺸﻔﻰ
ﻟﺫﻟﻙ ﻓﺈﻨﻪ ﻴﻭﺼﻰ ﺒﺈﺴﺘﻌﻤﺎل ﺍﻟﻠﻘﻨﻭﻜﻴﻥ ﺒﺎﻟﺯﺭﻕ ﺍﻟﻭﺭﻴﺩﻯ ﺒﺼﻭﺭﺓ ﺭﻭﺘﻴﻨﻴﻪ ﻟﻜل ﻋﻤﻠﻴﺎﺕ 
  .  ﺍﻟﺒﻁﻥ ﻭﺍﻟﺤﻭﺽ ﻟﺘﻘﻠﻴل ﺤﺩﻭﺙ ﺍﻟﺸﻠل ﺍﻟﻌﺼﺎﺒﻲ ﻭﺍﻻﻟﻡ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔ
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF TABLES 
 
 Page No.
Table 1:  Average age and weight of patients under study 26
Table 2: Mean time to occurrence of first bowel sound postoperatively  27
Table 3:  Passage of postoperative first flatus  28
Table 4: Incidence of postoperative pain among patients under study 29
Table 5:  Onset of pain/min 30
Table 6:  Frequency of an analgesic dose  31
Table 7:  Duration of Hospital Stay among patients under study 32
 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
 Page No. 
Figure 1:  Type of operation in the study groups 33
Figure 2:  Severity of postoperative pain in control group (n=20) 34
Figure 3:  Severity of postoperative pain in lignocaine group (n=20) 35
Figure 4: Mean systolic and diastolic blood pressure and pulse rate 
among control group   36
Figure 5: Mean systolic and diastolic blood pressure and pulse rate in 
lignocaine group   37
  
 
 
 
 
 
 1
INTRODUCTION 
Postoperative ileus is a concern among the surgical patients.(1) 
Following operations outside the abdomen there is a delay of about 16 hours 
before colonic activity returns. After abdominal operations the delay is form 
40 to 48 hours.(2) Epidural anaesthesia and analgesia was found to decrease 
the duration of ileus. This was related to the systemic absorption of local 
anaesthetic e.g. lignocaine.(1) Lignocaine is an amide local anaesthetic used 
in regional anaesthesia. It is also used parenterally for management of 
arrhythmias, and also for obtunding the automatic effects of intubations.(3) 
Lignocaine was used systemically to study its effect regarding postoperative 
ileus and postoperative pin.(4) Patients treated with lignocaine had less pain, 
faster return of bowel function and shorter hospital stay.   
In this study intravenous lignocaine was used pre-intra and postoperatively 
to study its effect among Sudanese patients regarding postoperative pin and 
duration of paralytic ileus, with the view that it may reduce the postoperative 
pain and the incidence of paralytic ileus and consequently reduce hospital 
stay.  
Ethical consideration: The study has been approved by the ethical 
committee of the faculty. A brief explanation of the procedure was given to 
the patients and their consent was taken verbally.  
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LITERATURE REVIEW 
Many clinical studies were done by various anaesthetists using 
lignocaine intravenously to evaluate postoperative analgesia and 
postoperative bowel motility.  
Paralytic ileus:  
Following abdominal and pelvic surgery, the motility of the 
gastrointestinal tract is temporarily impaired.2 This inhibition “postoperative 
ileus” is due to activation of spinal reflexes originating from the abdominal 
cavity with the sympathetic nerves as the efferent nerves.(5) This a dynamic 
ileus is characterized by nausea, inability to take oral feedings, and 
abdominal distention.4 It was found that, lignocaine intravenously will block 
these reflexes and produce postoperative pain relief, by impulse conduction 
block in small- diameter axons (a-delta and c-fibers).6 All these speeds the 
return of bowel function and shortens hospital stay in patients undergoing 
pelvic surgery.  
Rimback G, Cassuto J, and Per-Olof Tollessan studied the effect of 
continuous intravenous infusion of lignocaine on postoperative paralytic 
ileus in cholecystectomized patients in a double-blind study. An infusion of 
lidocaine (3 mg/mm, n=l 5) or an infusion of an equal volume of saline (n= 
15) was started 30 mm before induction of anesthesia and continued for 24 
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hours after surgery. Postoperative colonic motility was evaluated by radio 
opaque markers and serial abdominal radiographs. A record was kept of the 
first passage of gas and/or feces. Results showed significantly earlier return 
of propulsive motility in the colon of lidocaine-treated patients. Radio 
opaque markers in the lidocaine group were propelled significantly earlier 
from the cecumlascending colon to the transverse colon and appeared 
significantly earlier in the descending colon and the recto sigmoid colon than 
in saline- treated patients. Despite the fact the mean time for postoperative 
defecation occurred 17 hours earlier in lidocaine-treated patients, differences 
between the groups were not statistically significant a fact due, perhaps, to 
great individual variations in defecation habits. The time to first passage of 
gas, a variable representative of changes in anorectal or colonic tone rather 
than propagative motility, also did not differ significantly between the 
groups. No adverse reactions to lidocaine were reported. The results suggest 
that continuous intravenous infusion of lidocaine during the first 
postoperative day shortens the duration of paralytic ileus in the colon after 
abdominal surgery.(4) 
Wattwil M, Thoren T, Hennerdal, and J-E Garvill had conducted a 
study that was undertaken to compare the effects of postoperative 
bupivacaine epidural analgesia with those of intermittent injections of 
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Ketobemidone (a synthetic opioid) on postoperative bowel motility in 
patients who had had hysterectomies. The epidural group received 
continuous epidural analgesia with bupivacaine postoperatively for 26-30 
hours and the control group received intermittent injections of 
Ketobemidone for postoperative pain relief. Postoperative bowel movements 
and propulsive colonic motility were estimated from the first passage of 
flatus and feces, and by following radio opaque markers by serial abdominal 
radiographs. In the epidural group the time for first passing of flatus (31 ±22 
hours, mean ± SD) and feces ( 70 ± 44 hours ) were significantly shorter 
than in the control group ( flatus 58 ± 14 hours and feces 103 ± 26 hours). 
The average position of the markers was significantly more distally in 
epidural group immediately after operation and the markers continued to 
move forward during the first postoperative day. In the control group, the 
markers did not move during this period. The results demonstrate that 
postoperative bowel peristalsis returned earlier in the patients given epidural 
analgesia with bupivacaine or pain relief than in patients given a narcotic.5  
2- Pain: 
Pain is an extraordinarily complex sensation which is difficult to  
define and equally difficult to measure in an accurate objective manner. It 
has been define as the sensory appreciation of afferent nociceptive 
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stimulation which elicits an affective (or autonomic) component; both are 
subjected to rational interpretation by the patient. It may be presented as a 
Venn diagram. 
 
 
The interrelation ship between emotional, rational and physical 
components of pain. Perceived pain is represented by the area of 
intersection of the three components. (7) 
The shaded area represents the quantum of suffering experienced by 
the patient.  
The advantage of describing pain by means of the Venn diagram is 
that it may be seen instantly that the sensation of pain differs among 
individual patients; the emotional component varies with the patients’ 
previous experience, insight and motivation.  
Postoperative pain differs from other types of pain in that it is usually 
transitory, with progressive improvement over a relatively short time.  
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Typically effective component tends towards an anxiety state 
associated with diagnosis of the condition and fear of delay in provision of 
analgesic therapy by the attendants. In contrast, chronic pain is persistent, 
frequently with fluctuating intensity, and the affective components contains 
a greater depressive element. Thus, acute pain is more easily amenable to 
therapy than chronic pain.  
In the usual conception of pain, tissue damaging or threatening stimuli 
send neurophysiologic messages directly from the peripheral receptors to the 
sensory cortex via specific pathways in the peripheral and central nervous 
system. In this scheme, the greater the stimulation of the peripheral receptor, 
the more severe the pain.(7)  
Experience and research indicate that this concept of transmission of 
pain is incomplete, especially regarding chronic pain, and that the 
mechanism is in fact much more complex. Although definite channels for 
transmission of nociceptive nerve impulses do exist (a-delta and c fibers) in 
peripheral nerve, when this information reaches early synapses in the dorsal 
horn of the spinal cord, it is modified, dampened or augmented depending 
on many factors existing both within and without the organism.(8)  
In its more refractory forms, chronic pain can be influenced by the intensity 
of the stimulus, the interaction between this stimulus and afferent 
 7
modulating systems within the central nervous system (CNS), and most 
important by a variety of behavioral and learned strategies that augment or 
suppress the resulting neurophysiologic event. Thus, it is possible to have at 
one end of the spectrum a patient who has severe tissue injury but shows no 
sign of pain (e.g. athletes and soldiers in combat), and at the other end a 
patient who has no apparent tissue damage or source of injury, yet seems 
debilitated by chronic pain.(8)  
Intravenous injection of local anaesthetics to treat chronic pain of 
arthritis and other painful illnesses enjoyed considerable popularity in the 
l940 and l950s.(6)  
Graubard and Peterson, suggested that the intravenous administration 
of local anesthetics provided a measure of analgesia due to conduction block 
in nerve or nerve terminals.(6) 
Similarly de Jong have shown that intravenously administered 
lidocaine 5.0 to 17.5 mg/kg depresses response amplitude and coduction 
time in a-delta and c-fibers.(6)  
Chia YY, Tan PH, Wang KY, Liuk, successfully conducted a 
randomized, double-blind trial to assess the morphine-sparing effects of 
intravenous lignocaine in patients with acute pain. After major abdominal 
surgery, patients were treated with post-operative, patient-controlled 
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intravenous analgesia in two groups: M (n=25, morphine 0.2 mg/mi) and 
group IVIL (n=25, morphine 0.2 plus lignocaine 3.2 mg/mi). The patient 
controlled analgesia system was programmed to deliver a 5 ml bolus with a 
50 ml per 4 hours limit; the lockout time was 10 mm. Both groups closely 
resembled each other in terms of demographic data, pain intensity, 
cumulative morphine dose and the morphine-associated nausea, vomiting 
and purities. However, the sedation scores in group ML patients during the 
first post-operative day were significantly greater than those in group M. 
The incidence of lignocaine-reiated lightheadedness and dry mouth was also 
significantly greater in group Mt than in M. It was concluded that the 
addition of lignocaine 3.2 mg/mi to morphine 0.2 mg/mi given via patients- 
controlled analgesia system dose not provide a post-operative morphine 
sparing analgesic effect.(9)  
In a study carried out by Cahana A, Shverizon V, Ddberg 0, Magora 
FShir Y, 106 patients with neuropathic pain were treated with intravenous 
lignocaine during a period of 18 months (212 treatment sessions). Blood 
pressure, heart rate and pain scores were continuously monitored after an 
intravenous bolus of iignocaine 1 mg/kg, followed by continuous infusion of 
lignocaine 5mg/kg after one hour. There was significant pain relief after 
each session in most patients lasting from few hours to 4 weeks. There were 
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no significant side effects. The investigators thus recommended intravenous 
lignocaine injection for those with neuropathic pain unrelieved by other 
therapeutic moda1ities.(10) 
Forty patients undergoing radical retropubic prostatectomy were 
studied by Groudine, Fisher-HA, Kaufman-RP, Patel-MK, Wikins-LJ, 
Menta-SA, Lumb-PD one half of the patients received a lidocaine bolus 
(l.5mh/kg) and infusion (3mg/mm and 2mg/mm); the other half received a 
saline infusion. A blind observer recorded the patients daily pain score, the 
time the patient first experienced flatulence and had the first bowel 
movement, and the total use of analgesics. Lidocaine-treated patients first 
experienced flatulence in a significantly shorter. Lidocaine patients were 
also more comfortable postoperatively.(1)  
Lidocaine: 
Lidocaine hydrochloride is a local anaesthetic of the amide type.  
 
Chemical structure of lidocaine. (3) 
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Physical proprieties:   
 Lidocaine (Xylocaine) solution for injection is a sterile, isotonic 
aqueous solution. The pH of the solution is 5.0-7.0. The ampoules are free 
from preservatives and are intended for single use only.  
Lidocaine with adrenaline solution for injection is a sterile, isotonic aqueous 
solution. It contains sodium metabisulphite as an antioxidant. The pH of the 
solution is 3.3-5.0. The multidose vials contain preservative.(3)  
Pharmacology: 
Lignocaine is an aminoacyl amide and derivative of acetanilide. It  
produces general analgesia when given intravenously. Less than 10 percent 
is excreted in the urine and less than 7 percent is excreted into bile. The 
majority is broken down in the liver to monoethylglycine xylidide, and 
thence hydrolysed by liver amidases to 2.6-xylidine and 4-hydroxy-2,         
6-xylidine.(3)  
Metabolism of Lidocaine: 
The principal metabolic pathway of lidocaine is oxidative  
dealkylation in the liver to monoethylgycinexlidide followed by hydrolysis 
of this metabolite to xylidide.(11) 
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 Monoethylglycinexylidide has approximately 80% of the activity of 
lidocaine for protecting against cardiac dysrrhythmias in an animal model. 
This metabolite has a prolonged elimination half-time accounting for its 
efficacy controlling cardiac dysrhythmias after the infusion of lidocaine is 
discontinued. Xylidide has only approximately 10% of the cardiac 
antidysrrhythmic activity of lidocaine. In humans approximately 75% Of 
xylidide is excreted in the urine as 4-hydroxy-2,6-dimethy1aniline.’1  
Hepatic diseases or decreases in hepatic blood flow, which may occur during 
an aesthesia can reduce the rate of metabolism of lidocaine. For example, the 
elimination half-life of lidocaine is increased more than fivefold in patients 
with liver dysfunction compared with normal patients.”  
Decreased hepatic metabolism of lidocaine should be anticipated when 
patients are anaesthetized with volatile anaesthetics. Maternal clearance of 
lidocaine is prolonged in toxemia of pregnancy, and repeated administration 
of lidocaine can result in higher plasma concentrations than in normotensive 
patients.(11)  
Mode of action: 
Only the free base which has high lipid solubility is effective. It acts  
by preventing the depolarization of the axon which accompanies 
transmission of the action potential in the nerve.(3)  
 13
Central nervous system: 
Local analgesic can penetrate the blood/brain barrier and exert a  
similar stabilizing effect on central neurons. 
Overdose leads to tremors and restlessness proceeding to clonic 
convulsions.  
Lignocaine, have marked general properties, it has been used in 
continuous intravenous infusions to produce controllable analgesia during 
surgical operations and painful dressing.(3) 
Autonomic ganglia and myneural junction: 
Local analgesics can produce a degree of blockade of transmission at  
autonomic ganglia and at myoneural junction.(3) 
Cardiovascular system:-  
Local analgesics are also able to stabilize membrane permeability of 
excitatory tissue in the heart. They consequently increase the refractory 
period, prolong conduction time and depress myocardial excitability.  
Lidocaine has indirect cardiovascular effects (hypotension, bradycardia) 
which may occur after epidural or spinal administration depending on the 
extent of the concomitant sympathetic block.(3)  
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Respiratory system: -  
Central stimulation causes some increase in the rate of respiration, but 
as the medulla becomes depressed breathing becomes rapid and shallow. 
Bronchial musculature is relaxed. 
Local analgesics also have an atropine-like spasmolytic affect on 
smooth muscle and a mild antihistamine action.(3) 
 Pharmacokinetics: 
Lidocaine has a pka of 7.9, an oil/water partition coefficient of 2.9, 
and is 65% protein bound in plasma. 
The rat of absorption depends upon the dose, the route of 
administration and the vascularity of the injection site. Absorption is 
considerably slowed by the addition of adrenaline. Lidocaine has a total 
plasma clearance of 0.95 L/min a volume of distribution at steady state of 
91, an elimination half-life of 1.6 hours and an estimated hepatic extraction 
ratio of 0.65. The clearance of lidocaine is almost entirely due to liver 
metabolism, and depends both on liver blood flow and the activity of 
metabolizing enzymes. The elimination half-life in neonates 3.2 hours is 
approximately twice that of adults. Lignocaine readily crosses the placenta, 
and it is also excreted in breast milk.(3)  
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It has a rapid onset and a medium duration of action. It can be use for 
a number of anaesthetic techniques, including local infiltration, minor and 
major nerve block, spinal epidural block, and intravenous regional 
anaesthesia. It can also be used parentally to fulfill many important 
objectives e.g. it is used for the treatment and prevention of primary 
ventricular fibrillation complicating acute myocardial infarction and many 
arrhythmias.(3) 
Adverse effects: 
Stimulation of the CNS, is manifested by restlessness, excitement,  
nervousness, dizziness, blurred vision, nausea, vomiting, muscle twitching 
and convulsions.  
Excitation may be followed by depression, drowsiness, respiratory 
failure, and coma, depression of the cardiovascular system with pallor, 
sweating and hypotension. Arrhythmias, bradycardia, and cardiac arrest may 
be precipitated.  
Numbness of the tongue and perioral region is an early sign of 
systemic toxicity. 
- Allergic reactions.  
- Methaemoglobinaemia.(3)  
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Indications: 
• Infiltration anaesthesia. Nerve block.  
•  Epidural and caudal block and topical application.  
•  Spinal analgesia.  
•  Control of myocardial irritability and ventricular dysrrhythmias.  
•  Control of status epilepticus.  
•  Lignocaine given as slow intravenous injection produse general 
anaesthesia.(3)  
Precautions: 
Caution in the presence of hepatic insufficiency, cardiac conditions,  
epilepsy, myasthenia gravis, impaired respiratory function. The plasma half-
life of lignocaine may be prolonged in conditions which reduce hepatic 
blood flow such as cardiac and circulatory failure.  
Reduction of dosage in elderly, debilitated patients and children. The 
local anaesthetic effect may be reduced if the injection is made into an 
inflamed area with low tissue pH.(3)  
Contra-indications:  
• Allergy to lidocaine.  
•  Cardiogenic shock.  
•  Pre-existing conduction defects such as complete AV Block.  
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• History of severe neurologic disorders such as convulsions.  
• Severe hepatic impairment.(3) 
Children and any adult with ASA grading more than II were excluded.  
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OBJECTIVES  
 
This study was conducted to evaluate the effects of intravenous 
infusion of lignocaine on the following parameters: -  
1) Postoperative bowel function.  
2) Provision of adequate postoperative analgesia.  
3) Hospital stay.  
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PATIENTS AND METHODS 
This study was carried out on forty Sudanese patients scheduled for 
elective surgery at Khartoum Teaching Hospital and Soba University 
Hospital during the period from the 1st of May 2001 to 31st of October 
2001.  
Study designs: 
This study is a prospective comparative study evaluating the role of  
lignocaine in producing post-operative analgesia, speed for return of bowel 
function and shortening of hospital stay.  
Study population: 
Patients undergoing general anesthesia for hysterectomy, 
myomectomy, prostatectomy and major pelvic surgery.  
Female were 35, age (25-65 years).  
Male were 5, age (58-65 years).  
Inclusion criteria: 
Patients are of ASA grade I& II.  
Exclusion criteria: 
Children and any adult with ASA grading more than II were  
excluded.  
 
 20
Methodology: - 
Patients were divided into two groups as follows:  
a) 20 patients control group receiving a saline.  
b)  20 patients receiving lignocaine intravenously.  
An intravenous (I.V.) line was secured using an I.V. cannula size 18 
gauge on the dorsum of the hand; I.V. fluids in the form of normal saline or 
dextrose 5% with normal saline were then started.  
A bolus dose of lignocaine (1 .5mg/kg) was given to patients of the 
first group one hour prior to induction of anaesthesia. Pulse rate, blood 
pressure a respiratory rate were monitored pre-intra and postoperatively and 
recorded every 10 minutes. 
All patients received atropine, thiopentone or propofol and intubated 
using suxamethonium.  
All patients were maintained by oxygen and nitrous oxide, calculated 
dose of muscle relaxant (pancuronium) and 25mg pethidine.  
In the lignocaine group, lignocaine infusion was initiated at 3mg/mm in the 
patients who weighted ≥ 70 kg. Those less than 70 kg received 2mg/mm of 
lignocaine. Lignocaine continued throughout surgery and into the 
postanaesthesia care unit (PACU).  
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The infusion of lignocaine was terminated 60 mm after skin closure. 
All patients were monitored, using a dynamap monitoring blood pressure 
and heart rate and an ECG monitor.  
Respiratory rate was monitored using watch.  
For postoperative pain: 
Pain was scored as, 0 = nil, 1 = mild, 2= moderate, 3= sever.  
Data analysis: 
The data collected was analyzed using master sheet and SPSS  
computerized programme for data analysis. Figures were worked out in the 
Excel computer programme. For hypothesis testing, Chi 2 and student t test 
were used for qualitative and quantitative data respectively; 0.05 probability 
level was predetermined level of significance.  
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RESULTS 
Twenty patients received intravenous bolus dose of lignocaine one 
hour before induction of anaesthesia, while another twenty were control 
received no lignocaine.  
The mean age of the control group was 41 .4SOyrs, and that of the 
lignocaine group was 41.l5Oyrs, (P= 0.85485); (Table 1), i.e. no significant 
changes between the groups.  
The mean weight of the control group was 64.750 kg. The mean 
weight of the lignocaine group was 63.850 kg, (P= 0.8 1117); (Table 1).  
Type of operation: 
Myomectomy was done for 55% of control group and 45% of  
lignocaine group.  
Hysterectomy was done for 30% of control group and 45% of 
lignocaine group. 
Prostatectomy was done for 15% of control group and 10% of 
lignocaine group (Figure 1). 
Bowel sound:  
The mean time to return of bowel sounds in control group was  
33.700 hours while it was 17.500 hours in lignocaine group (P= 0.003272); 
(Table 2).  
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Postoperative first flatus: 
The mean time to postoperative first flatus was 53.900 hours in  
control group and 29.750 hours in lignocaine group (P= 0.018321);  
(Table 3).  
Pain and analgesia: 
Perception of pain:  
All twenty patients experienced postoperative pain in the control 
group, while 4 patients complained of pain in the lignocaine group (p= 
0.00000 1); (Table 4).  
1) Control group:  
Two patients (10%) experienced moderate pain, while 18 (90%) had 
severe pain (Figure 2).  
2) Lignocaine group:  
Sixteen patients from 20 (80%) had no pain. Three (15%) had mild 
pain, while one (5%) had moderate pain. No patients experienced sever pain 
(Figure 3).  
The onset time of pain in control group was 30.0 mm, while in the 
lignocaine group was 90.0 mm (P= 0.005); (Table 5).  
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Concerning analgesics requirement all patients in the control group 
needed supplementary analgesia while only twenty percent from the 
lignocaine group needed analgesia (P =0.005); (Table 6).  
Eighty percent of patients in ligoncaine group were comfortable 
without any analgesics.  
A result which was found to be significant (P = 0.005); (Table 6).  
Frequency of analgesic dose: 
All patients in the control group received analgesia while 16 (80%)  
patients in lignocaine group received none.  
Thirty percent in the control group needed analgesia four times while 
the maximum requirement in the lignocaine group was three times (P= 
0.005); (Table 6).  
Side effects: 
No patient in the two groups suffered from hypotension, bradycardia,  
convulsions, or ECG changes.  
Haemodynamic changes: 
Diastolic blood pressure of the control group ranged from 76-102  
mmHg.  
Diastolic blood pressure of the lignocaine group ranged from 70-104 
mmHg (P = 0.476333). 
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Systolic blood pressure of the control group ranged from 110-160 
mmHg.  
Systolic blood pressure of the lignocaine group ranged from 115-150 
mmHg (P= 0.34560130).  
The pulse rate of the control group ranged from 76-1 00/mm. The 
pulse rate of the lignocaine group ranged from 72-98/mm (p= 0.563497).  
No significant haemodynamic changes were found between the two 
groups (Figures 4 & 5).  
Hospital stay: 
The majority of patients in control group 14 (60%) remind in hospital  
for 6-8 days while the majority of patients in lignocaine group 17(85%) 
remind for only 1-5 days. 
The mean duration of hospital stay in control group was 6.9 days, 
while it was 4.4 days in lignocaine group (P= 0.001101); (Table 7).  
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DISCUSSION  
 
Postoperative ileus can cause nausea, vomiting and pain and it adds to the 
expense of surgery.1 It is in the interest of patient care to minimize the 
duration of surgically induced ileus.  
In this study the return of bowel sounds postoperatively was found to 
be more rapid in lignocaine group mean time 17.5 hours than the control 
group mean time 33.7 hours. This was statistically significant (p 0.05). Also 
the occurrence of postoperative first flatus was found more early in the 
lignocaine group 29.750 hours than the control group mean time 53.900 
hours and this difference is statistically significant (P 0.05). These results are 
comparable with results of Rimbck and the results of Wattwil M.1’5  
Groudine-SB,” and Cahana A,10 found a significant pain relief in patients 
with neuropathic pain unrelieved by other therapeutic modalities, and in 
patients post-retropubic prostatectomy after been given intravenous 
lignocaine. In this study the lignocaine group had significantly less pain than 
the control group.  
The time of onset of pain the lignocaine group was significantly 
longer than the time of the control group. Also patients of the lignocaine 
group received less frequent doses of analgesia than control group. 
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The average duration of hospital stay for patients in control group was 
6.9 days and for patients in the lignocaine group was 4.4 days. This was a 
significantly shorter duration in the lignocaine treated patients than the 
control group (p 0.05).  
These results agreed with those found by Groudine-SB, Fisher-HA, 
Scott Cardiovascular side effects related to lignocaine e.g. arrhythmias, 
hypotension and convulsions were not recorded in this study. So it appears 
that lignocaine is a safe drug when given on weight bases to healthy 
subjects.  
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CONCLUSION 
 
• Intravenous infusion of lignocaine following a bolus intravenous dose 
started preoperatively and extending to the postoperative hour 
significantly decreases the time to return of bowel sounds and the time 
to post operative first flatus, hence decreasing the duration of 
postoperative paralytic ileus.  
•  These same regimens of lignocaine significantly reduces 
postoperative pain and its intensity.  
•  Haemodynamics are stable with lignocaine.  
•  This regimen of intravenous lignocaine is not associated with any 
serious side effects.  
•  Hospital stay is significantly reduced by the use of the above 
mentioned regimen of lignocaine.  
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RECOMMENDATIONS 
• The use of intravenous lignocaine preoperatively is to be encouraged for 
abdominal and pelvic operations to reduce the incidence of paralytic ileus 
and postoperative pain.  
•  The use of intravenous lignocaine followed by lignocaine is to be adopted 
as one of the methods of providing postoperative analgesia when indicated 
as it is safe effective and economical and it significantly reduces hospital 
stay.  
•  Further study on larger population of patients is needed.  
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Intravenous lidocaine speeds the return of bowel function, decreases  
postoperative pain, and shortens hospital stay in patients under going major 
pelvic surgery.  
 
Patient data form  
Case No:  
Name: …………. 
Age: …………. 
Gender ………….                      Wt …………. 
Diagnosis: …………. 
Operation: …………. 
Other disease: …………. 
Medication:  
Lignocaine:             Yes                    No  
Haemdynamic parameters:   
Time/mm 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130,  
Bp  
Pulse  
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Side effects:              Hypotension                           Bradycardia  
                                  Convulsions                           ECG changes  
Postoperative pain:    Yes  
Onset of pain             mins after skin closure  
Severity:                    Mild                          Moderate                   Severe  
Postoperative pain medication:  
               Opioid                mg                     Non opioid                 mg 
Frequency of analgesia:  
Total dose of analgesic needed                        mg  
Bowel sounds present after skin closure          mins  
First flatus passed:                                    mm after skin closure  
Hospital stay              24 hours       1/day           2/days         3/days      4/days  
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